Total Nutraceutical (ERGO) 0.0700 $ERGO
UPDATE -- Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2(R) Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
GlobeNewswire - Mon Dec 21, 2:12PM CST
Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected initial enrollment in Entia's Chronic Kidney Disease study. This milestone was achieved during his recent kickoff visit to the study's test sites in Columbia (South America) and on the Caribbean island of Bonaire. The initial enrollees represent more than 25% of the quantity of study participants ultimately anticipated to enroll.
Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2(R) Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
GlobeNewswire - Mon Dec 21, 7:50AM CST
Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected initial enrollment in Entia's Chronic Kidney Disease study. This milestone was achieved during his recent kickoff visit to the study's test sites in Columbia (South America) and on the Caribbean island of Bonaire. The initial enrollees represent more than 25% of the quantity of study participants ultimately anticipated to enroll.
Ergomed Increases Its Co-Development Contribution up to $12,000,000 in CEL-SCI's Phase 3 Head and Neck Cancer Trial
BusinessWire - Mon Oct 05, 7:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company"
and its Clinical Research Organization (CRO) Ergomed plc (AIM:ERGO) today announced that they have expanded their co-development agreement with increased activities to be undertaken by Ergomed. Pursuant to the expanded co-development agreement, Ergomed's contribution to the Phase 3 study will increase from $10,000,000 to $12,000,000. The companies are undertaking the Phase 3 trial of CEL-SCI's investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer.
CVM: 0.48 (+0.01)
Entia Biosciences, Inc. Names Chief Executive Officer to Manage Growth of Consumer Health Products and To Launch New Medical Food Brands
ACCESSWIRE - Thu Aug 13, 8:55AM CDT
New Business Strategy to Capitalize on Unique, Innovative and Proprietary Entia Products
Entia Biosciences CEO Dr. Hausman to Represent GROH(R) at Cosmoprof North America
ACCESSWIRE - Thu Jul 09, 1:13PM CDT
PORTLAND, OR / ACCESSWIRE / July 9, 2015 / Entia Biosciences, Inc. (OTCQB: ERGO), is excited to announce Dr. Marvin S. Hausman, MD and CEO will be representing the Company's GROH(R) Professional brand of hair and skin care products at Cosmoprof North America (CPNA), the largest international B2B beauty event in the Americas.
Entia Biosciences CEO Dr. Hausman to Represent GROH at Cosmoprof North America
eTeligis - Thu Jul 09, 12:57PM CDT
PORTLAND, OR, United States, via ETELIGIS INC., 07/09/2015 - - Entia Biosciences (OTCQB: ERGO), is excited to announce Dr. Marvin S. Hausman, MD and CEO will be representing the Company's GROH(R) Professional brand of hair and skin care products at Cosmoprof North America (CPNA), the largest international B2B beauty event in the Americas.
Entia Biosciences CEO and SAB Member Invited to Chair Sessions and Speak at 17th International Functional Food Conference
ACCESSWIRE - Fri Nov 14, 9:15AM CST
SHERWOOD, OR / ACCESSWIRE / November 14, 2014 / Entia Biosciences Inc. (OTCQB: ERGO), an emerging leader in the field of nutrigenomics, announces that Marvin S. Hausman MD, CEO, will speak on the subject - "Treatment of Anemia with a Natural Mushroom-Based Medical Food ErgoD2." The 17th International Conference of FFC, Discovery, Utilization, and Control of Bioactive Components and Functional Foods, November 18-19, 2014, will be held at the University of San Diego, San Diego, California, USA.
UPDATE -- Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2(R) Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
GlobeNewswire - Mon Dec 21, 2:12PM CST
Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected initial enrollment in Entia's Chronic Kidney Disease study. This milestone was achieved during his recent kickoff visit to the study's test sites in Columbia (South America) and on the Caribbean island of Bonaire. The initial enrollees represent more than 25% of the quantity of study participants ultimately anticipated to enroll.
Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2(R) Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
GlobeNewswire - Mon Dec 21, 7:50AM CST
Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected initial enrollment in Entia's Chronic Kidney Disease study. This milestone was achieved during his recent kickoff visit to the study's test sites in Columbia (South America) and on the Caribbean island of Bonaire. The initial enrollees represent more than 25% of the quantity of study participants ultimately anticipated to enroll.
Ergomed Increases Its Co-Development Contribution up to $12,000,000 in CEL-SCI's Phase 3 Head and Neck Cancer Trial
BusinessWire - Mon Oct 05, 7:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company"
and its Clinical Research Organization (CRO) Ergomed plc (AIM:ERGO) today announced that they have expanded their co-development agreement with increased activities to be undertaken by Ergomed. Pursuant to the expanded co-development agreement, Ergomed's contribution to the Phase 3 study will increase from $10,000,000 to $12,000,000. The companies are undertaking the Phase 3 trial of CEL-SCI's investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. CVM: 0.48 (+0.01)
Entia Biosciences, Inc. Names Chief Executive Officer to Manage Growth of Consumer Health Products and To Launch New Medical Food Brands
ACCESSWIRE - Thu Aug 13, 8:55AM CDT
New Business Strategy to Capitalize on Unique, Innovative and Proprietary Entia Products
Entia Biosciences CEO Dr. Hausman to Represent GROH(R) at Cosmoprof North America
ACCESSWIRE - Thu Jul 09, 1:13PM CDT
PORTLAND, OR / ACCESSWIRE / July 9, 2015 / Entia Biosciences, Inc. (OTCQB: ERGO), is excited to announce Dr. Marvin S. Hausman, MD and CEO will be representing the Company's GROH(R) Professional brand of hair and skin care products at Cosmoprof North America (CPNA), the largest international B2B beauty event in the Americas.
Entia Biosciences CEO Dr. Hausman to Represent GROH at Cosmoprof North America
eTeligis - Thu Jul 09, 12:57PM CDT
PORTLAND, OR, United States, via ETELIGIS INC., 07/09/2015 - - Entia Biosciences (OTCQB: ERGO), is excited to announce Dr. Marvin S. Hausman, MD and CEO will be representing the Company's GROH(R) Professional brand of hair and skin care products at Cosmoprof North America (CPNA), the largest international B2B beauty event in the Americas.
Entia Biosciences CEO and SAB Member Invited to Chair Sessions and Speak at 17th International Functional Food Conference
ACCESSWIRE - Fri Nov 14, 9:15AM CST
SHERWOOD, OR / ACCESSWIRE / November 14, 2014 / Entia Biosciences Inc. (OTCQB: ERGO), an emerging leader in the field of nutrigenomics, announces that Marvin S. Hausman MD, CEO, will speak on the subject - "Treatment of Anemia with a Natural Mushroom-Based Medical Food ErgoD2." The 17th International Conference of FFC, Discovery, Utilization, and Control of Bioactive Components and Functional Foods, November 18-19, 2014, will be held at the University of San Diego, San Diego, California, USA.
